Chronic obstructive pulmonary disease (COPD) is a progressive chronic lung disease characterized by persistent airflow limitation, typically including chronic bronchitis and emphysema, and associated with breathlessness, cough, and exacerbations.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
Merck will acquire Terns Pharmaceuticals for $6.7 billion to bolster its cancer pipeline ahead of Keytruda's 2028 patent expiration. The deal gives Merck access to TERN-701, an oral tyrosine kinase inhibitor for chronic myeloid leukemia. Merck projects over $70 billion in commercial opportunities from its pipeline by the mid-2030s.
The FDA has expanded approval of GSK's Arexvy RSV vaccine to include adults aged 18 to 49 years at increased risk for lower respiratory tract disease, based on phase 3b trial data showing noninferior immune response.
New real-world effectiveness data presented at RSVVW'26 demonstrate that GSK's Arexvy RSV vaccine was associated with a 75.6% reduction in RSV-related hospitalizations among adults aged 60 and older, with exploratory findings suggesting potential benefits for cardiovascular and respiratory complications.
Pfizer's tilrekimig met its primary endpoint in a mid-stage eczema trial and will advance to late-stage testing. Separately, oral remibrutinib demonstrated rapid efficacy in treating peanut allergy in a phase II study.
Upstream Bio presented additional Phase 2 VIBRANT trial data showing verekitug reduced nasal polyp scores and congestion in chronic rhinosinusitis patients, while Phase 2 VALIANT trial results demonstrated significant reductions in asthma exacerbations with multiple dosing regimens.
AstraZeneca has completed a Phase IIb heart failure trial for AZD5462, finished a real-world breast cancer study in Brazil, and is recruiting for an observational COPD study in heart clinic patients.
Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.
Phase III KALOS and LOGOS trial results published in The Lancet Respiratory Medicine show Breztri Aerosphere improved lung function and reduced severe asthma exacerbations compared to dual-combination therapies in patients with uncontrolled asthma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07595588 |
Virtual Reality Cave vs. Simulated Home for Community Nursing Education: A Crossover Trial Comparing Student Competence, Confidence, and Satisfaction |
COMPLETED | NA |
| NCT07579052 |
CLEAR Model for Predicting Ventilatory Liberation in Severe COPD |
RECRUITING | |
| NCT07566195 |
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations |
RECRUITING | PHASE3 |
| NCT07549932 |
Adjunctive Role of Statin Therapy on Airway Inflammation and Clinical Consequences of Chronic Obstructive Pulmonary Disease |
COMPLETED | NA |
| NCT07512687 |
Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia |
NOT_YET_RECRUITING | NA |
| NCT07493798 |
Serum Potassium Prediction Using Machine Learning and Single-lead ECG |
WITHDRAWN | |
| NCT07474220 |
Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease |
NOT_YET_RECRUITING | |
| NCT07464587 |
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease |
NOT_YET_RECRUITING | PHASE3 |
| NCT07440420 |
Evaluation of an AR-Assisted System for Standardizing Spirometry |
NOT_YET_RECRUITING | NA |
| NCT07418736 |
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease |
RECRUITING | PHASE2 |
